591 Comparison of two oHSV Vectors for the treatment of glioblastoma
Main Authors: | Joseph Jackson, Bonnie Hall, Lisa Bailey, E Chiocca, Justus Cohen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
by: Joseph W. Jackson, et al.
Published: (2021-09-01) -
GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
by: Paola Sette, et al.
Published: (2019-12-01) -
STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
by: Joel M. Lee, et al.
Published: (2019-12-01) -
Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
by: Tatiana Gianni, et al.
Published: (2021-09-01) -
oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
by: Wen Zhang, et al.
Published: (2020-03-01)